Inborn errors of metabolism:

Indications for: SCENESSE

To increase pain free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.

Adult Dosage:

See full labeling. Use an SFM implantation cannula or other suitable devices. ≥18yrs: Insert 1 implant subcutaneously above the anterior supra-iliac crest every 2 months.

Children Dosage:

<18yrs: not established.

SCENESSE Warnings/Precautions:

Should be administered by an experienced health care provider. Pre-existing nevi and ephelides. Monitor skin pigmentary lesions; perform full body skin exam twice yearly. Advise patients to maintain sun and light protection measures during treatment to prevent phototoxic reactions. Pregnancy. Nursing mothers.

SCENESSE Classification:

Melanocortin receptor agonist.

Adverse Reactions:

Implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract infection, non-acute porphyria, skin irritation; skin pigmentation/darkening.

Drug Elimination:

Half-life: ~15 hours.

Generic Drug Availability:


How Supplied:

Implant (in vial)—1